Stock Traders Buy High Volume of Call Options on Inventiva (NASDAQ:IVA)

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the target of unusually large options trading activity on Wednesday. Stock traders acquired 40,232 call options on the stock. This represents an increase of 201,060% compared to the typical daily volume of 20 call options.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Tuesday, April 21st. Truist Financial assumed coverage on Inventiva in a report on Thursday, March 19th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, Wall Street Zen cut Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $16.56.

Inventiva Trading Down 2.4%

NASDAQ IVA traded down $0.09 during trading on Wednesday, reaching $3.69. The company’s stock had a trading volume of 1,724,725 shares, compared to its average volume of 556,902. Inventiva has a twelve month low of $2.85 and a twelve month high of $7.98. The business’s fifty day moving average price is $4.62 and its 200-day moving average price is $5.33.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.01 million during the quarter. Analysts expect that Inventiva will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On Inventiva

A number of institutional investors have recently modified their holdings of IVA. Creative Planning acquired a new position in shares of Inventiva in the 2nd quarter valued at approximately $32,000. Millennium Management LLC acquired a new stake in Inventiva in the third quarter valued at about $649,000. NewEdge Advisors LLC bought a new position in Inventiva in the third quarter valued at about $116,000. UBS Group AG grew its position in Inventiva by 28,881.6% in the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after acquiring an additional 2,634,580 shares during the last quarter. Finally, Simplify Asset Management Inc. acquired a new position in Inventiva during the fourth quarter worth about $1,570,000. 19.06% of the stock is owned by institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.